NCT01820481

Safety and Efficacy of WIN-901X in Asthma

Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 209 (actual)
• Sponsor: Whanin Pharmaceutical Company · Industry
• Sex: All
• Age: 20 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.

Detailed description

Double blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	WIN-901X dose level 1	100mg Bid, PO, 12weeks
DRUG	WIN-901X dose level 2	200mg Bid, PO, 12weeks
DRUG	WIN-901X dose level 3	300mg Bid, PO, 12weeks
DRUG	Placebo	Bid, PO, 12weeks

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-11-01
• Completion: 2013-11-01
• First posted: 2013-03-28
• Last updated: 2013-12-09

Locations

1 site across 1 country: South Korea